VivoSeq
Oncology

CNS Malignancies

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

CNS Malignancies is an early-stage landscape with 0 programs across 1 company. The most active players are SynerGene Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SynerGene Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Terminated1 · 33%
Not yet recruiting1 · 33%
Unknown status1 · 33%

Clinical Trials

Trial Activity

Mapping Draining Lymph Nodes in CNS Malignancies
Terminated·WWashington University School of Medicine·Phase 1·NCT04096716·14 enrolled
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
Not yet recruiting·—·Phase 1·NCT07017816·18 enrolled
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
Unknown status·SSynerGene Therapeutics, Inc.·Phase 1·NCT03554707·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)